HomeRNTX • NASDAQ
Rein Therapeutics Inc
add
Market news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 5.61M | -22.15% |
Net income | -5.50M | 22.66% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -5.59M | 21.73% |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 7.43M | -38.32% |
Total assets | 57.63M | -41.90% |
Total liabilities | 7.75M | -1.39% |
Total equity | 49.88M | — |
Shares outstanding | 22.15M | — |
Price to book | 8.82 | — |
Return on assets | -23.41% | — |
Return on capital | -26.90% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Mar 2025info | Y/Y change |
|---|---|---|
Net income | -5.50M | 22.66% |
Cash from operations | -6.18M | -17.15% |
Cash from investing | — | — |
Cash from financing | 738.00K | — |
Net change in cash | -5.44M | -3.15% |
Free cash flow | -3.39M | 12.40% |
Previous close
$1.94
Day range
$1.84 - $1.99
Year range
$1.35 - $4.40
Market cap
43.20M USD
Avg Volume
46.50K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Founded
2001
Headquarters
Website
Employees
11
